A year ago, Vaxart looked like a company with a government backstop. BARDA, the federal agency that funds pandemic preparedness, had committed hundreds of millions of dollars to help Vaxart develop an oral COVID vaccine, the kind you swallow as a pill rather than receive as a shot. That contract made the company’s quarterly revenue look almost corporate. Then, in August 2025, BARDA issued a partial termination and a string of stop-work orders. By the third quarter of 2026, quarterly revenue had fallen to $10.6 million, a drop of roughly 85% in twelve months. The same company, the same science, a radically different financial picture.
That contrast is the story. Vaxart’s underlying technology, an oral vaccine platform that could one day replace needles for common respiratory illnesses, has not changed. What changed is who is paying for it, and whether the cash on hand lasts long enough for the science to matter.
The quick read
The filed numbers show a company whose revenue was almost entirely government-funded, and that funding has been gutted in practice by stop-work orders. Cash on hand as of September 30, 2026 covers operations only into the second quarter of 2027, about six to eight months from today. The oral COVID trial has been closed to enrollment since August 2025, when a BARDA stop-work order halted screening after roughly half of the targeted 10,000 participants had been enrolled. Primary results are expected in May 2027, right at the edge of the runway. The open question: does the science produce a result before the money runs out?
How the contract became the company
Vaxart spent years as a small biotech with an interesting idea: vaccines delivered as pills, using the body’s gut immune system rather than a needle in the arm. The platform is genuinely novel. But novel science needs funding, and Vaxart found it in the post-pandemic government push for next-generation vaccines. The BARDA contract, formally called the ATI-RRPV Contract, was the company’s financial spine.
When BARDA issued stop-work orders in mid-2025 and then cut the authorized ceiling by more than a hundred million dollars through Modification No. 7, the effect was immediate. R&D spending, which had been running at a high level because the government was reimbursing it, fell to a fraction of its prior rate in Q3 2026. That sounds like discipline. It is actually the sound of the work that generated the revenue stopping.
The contract was cut, not cancelled, and the difference matters. It remains in force, and the same filing records funding available for payment rising from $331.0 million to $336.4 million during the quarter, money attached to following the participants already enrolled through to a result. What collapsed was the reimbursable work, and with it the revenue. The agreement itself is still there, about a quarter smaller than it was.
The net loss widened meaningfully over the same comparison, even as spending fell, because the revenue that had been covering costs simply disappeared. Think of it like a contractor whose client pauses a renovation mid-build: the crew costs less to run, but the income is gone, and the half-finished structure still needs finishing.
What the cash says
As of September 30, 2026, Vaxart held $65.5 million in cash, equivalents, and short-term investments. The BARDA contract had by then paid out $278.0 million in cumulative cash, which is the scale of what the stop-work orders interrupted. Management stated in the filing that this is expected to fund operations into the second quarter of 2027. That is the math: roughly six to eight months of runway from today’s date.
The mood, meaning what the market is currently pricing in, is harder to read without a live quote, but the structure is clear. A biotech with less than a year of cash and no commercial revenue is priced on hope, not earnings. It is also no longer priced on Nasdaq. Trading in the shares was suspended on 8 July 2025 and the company was formally delisted on 1 December 2025; the stock has been quoted on OTCQX since. The filing spells out one consequence: because OTCQX securities are not “covered securities”, offers and sales must now comply with each state’s blue sky laws, which the company describes as introducing additional compliance obligations. For a company whose next financing is the entire question, a narrower buyer base and a costlier raise are not footnotes. The gap between what the filed numbers justify and what any optimistic valuation requires is filled entirely by the clinical trial calendar.
The trial that has to deliver
Vaxart’s oral COVID vaccine candidate, VXA-CoV2-3.3, is in a Phase 2b trial that tests it head to head against an approved mRNA vaccine, with a primary completion date of May 2027. It was designed for 10,000 participants and will not get them. The company completed a 400-participant sentinel cohort in the second half of 2024, and an independent data safety monitoring board recommended in January 2025 that the study proceed without modifications. A February 2025 stop-work order was lifted that April, BARDA approved dosing of the main cohort in May 2025, and in August 2025 a second stop-work order halted screening and enrollment after about half the target had enrolled. ClinicalTrials.gov now lists the study as active, not recruiting, with enrollment of 5,485. The company’s own filing says the stop-work orders “halted enrollment and therefore reduced the size of the study.” A trial powered for 10,000 and stopped at roughly half that is a different instrument, and that matters to how its result should be read.
The norovirus program, which causes the stomach illness that sweeps through schools and cruise ships, showed promising Phase 2 results as of late 2024, and a quadrivalent version is planning a Phase 3 study. But planning a Phase 3 costs money Vaxart does not yet have committed.
Nor is Vaxart only its own balance sheet, and this is the part that makes the readout more binary than it first appears. In November 2025 the company granted Dynavax an exclusive worldwide licence to develop and commercialise the oral COVID candidate. Dynavax paid $25 million upfront and bought $5 million of stock. Sanofi completed its acquisition of Dynavax in February 2026. Under the agreement, once the Phase 2b finishes and an end-of-Phase 2 meeting with the FDA has happened, Dynavax may elect, in its sole discretion, to take over continued development. If it so elects, it pays Vaxart a further $50 million.
That reframes the race. The readout does not merely reopen a conversation with funders. It triggers a contractual decision by a Sanofi subsidiary, worth $50 million in non-dilutive cash, at a moment when the company expects to have months of runway left. A good result is worth more than the trial data alone. A poor one removes the most likely source of money that does not dilute existing holders.
The timing is tight in a way that concentrates the mind. Primary COVID results are due in May 2027. The runway ends around the same month. If the trial reads out well, it reopens the conversation with funders, partners, and potentially BARDA itself. If it does not, or if it is delayed, the company faces a financing decision with no obvious cushion.
Reading the numbers
- $10.6 million in Q3 2026 revenue (down from $72.4 million in Q3 2025, per the 10-Q filed November 5, 2026). What it means: nearly all of Vaxart’s income was government reimbursement for work done under the BARDA contract. When the work stopped, so did the income. A household analogy: a family earning $7,200 a month from a consulting contract sees it cut to $1,060 because the client paused the project. The bills did not pause.
- $344.8 million authorized ceiling (reduced from $460.7 million via Modification No. 7, per the same filing). What it means: even if the contract resumes fully, the maximum BARDA will ever pay is now $116 million smaller than originally agreed. That ceiling reduction is permanent, not a pause.
- $65.5 million cash and investments as of September 30, 2026, with a stated runway into Q2 2027. What it means: at current burn, this is roughly six to eight months of operating life. A household with $65,500 in savings and monthly expenses of roughly $9,000 to $10,000 can see exactly how long that lasts without new income.
Correction, 18 November 2026: this article originally stated that the Phase 2b COVID trial was still enrolling toward 10,000 participants. Enrollment was halted in August 2025 by a BARDA stop-work order at roughly half that number, and the study is listed as active, not recruiting. The article also did not note that the trial is a head-to-head comparison against an approved mRNA vaccine. Both have been corrected, and a sentence dating the sentinel-cohort safety review to July 2026 has been replaced with the dates stated in the company’s filing. We thank the reader who raised it.
Update, 19 November 2026: the headline originally read “A Government Contract Collapses”. The 2024 ATI-RRPV contract was reduced, not terminated, and the 10-Q records funding available for payment rising from $331.0 million to $336.4 million in the quarter; the headline and the relevant passage have been changed to say so. This version also adds the Dynavax licensing agreement, which the original omitted, and replaces a clause left dangling by the 18 November correction. Raised by a reader.
Addition, 19 November 2026: this article did not originally record that Vaxart was delisted from Nasdaq on 1 December 2025 and has traded on OTCQX since. That is material to a piece about financing risk and it has been added. It came to our attention through a reader arguing the coverage was too negative.
Addition, 19 November 2026: the description of the Dynavax agreement has been expanded to record the $25 million upfront payment, the $5 million equity purchase, and Dynavax’s right to pay a further $50 million if it elects to assume continued development after the end-of-Phase 2 meeting. Cumulative BARDA cash receipts of $278.0 million have also been added. Both come from the company’s filings and both were prompted by readers.
Sources
- Vaxart 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
- Vaxart Q3 2026 business update and earnings release
- ClinicalTrials.gov: NCT06672055 (VXA-CoV2-3.3 Phase 2b trial)
- Vaxart 10-Q for quarter ended September 30, 2025 (SEC EDGAR, prior-year comparison)









